Senti Biosciences Holdings SNTI
NASDAQ SNTI
$0.31 +0.01 (+4.40%)
As of: Sep 10, 2026 · 11:24 AM EDT

Senti Biosciences Holdings (SNTI) Income from Discontinued Operations (2022 - 2023)

Senti Biosciences Holdings (SNTI) posted Income from Discontinued Operations of -$28000.0 for Q4 2023, down 100.13% on a QoQ basis from $21.7 million in Q3 2023, and up 99.67% year-over-year from -$14023.0 in Q4 2022.

Analysis

Senti Biosciences Holdings (SNTI) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

Senti Biosciences Holdings has reported Income from Discontinued Operations for 2 years, with the latest figure at -$28000.0 in Q4 2023.

  • On a quarterly basis, Income from Discontinued Operations rose 99.67% year-over-year to -$28000.0 in Q4 2023; TTM through Sep 2024 was -$28000.0, a 100.73% decrease from a year earlier, with the FY2023 full-year figure at $12.3 million, up 244.51% from the prior year.
  • Income from Discontinued Operations was -$28000.0 for Q4 2023 at Senti Biosciences Holdings, down from $21.7 million in the prior quarter.
  • The five-year high for Income from Discontinued Operations was $21.7 million in Q3 2023, with the low at -$8.5 million in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.02 Bn 5.02 Bn - -
3 Iovance Biotherapeutics 3.64 Bn 3.34 Bn 55.72 Mn -
4 Legend Biotech 3.56 Bn 2.60 Bn 251.50 Mn -
5 uniQure 3.01 Bn 3.01 Bn 5.49 Mn -
6 Beam Therapeutics 2.54 Bn 2.54 Bn - -
7 Precigen 2.36 Bn 2.36 Bn 52.17 Mn -
8 Sarepta Therapeutics 2.19 Bn 1.40 Bn 251.87 Mn -
9 Vericel 1.96 Bn 1.80 Bn 56.40 Mn -
10 Senti Biosciences Holdings 9.61 Mn 9.61 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -28,000.00
Sep 30, 2023 21.69 Mn
Jun 30, 2023 -4.45 Mn
Mar 31, 2023 -4.87 Mn
Dec 31, 2022 -8.55 Mn
Sep 30, 2022 -2.34 Mn